BioSpace’s Post

Discover the Future of AI Drug Discovery with Syntekabio at BIO! 📍 Visit us in Booth #5435 at the San Diego Convention Center, June 3-6, 2024. Explore how Syntekabio de-risks and streamlines drug discovery with our robust #AI-driven platforms. Leveraging our powerful infrastructure, we rapidly discover and deliver both small molecules and biologics, including antibodies and neoantigens. We experimentally validate our work in cooperation with our global CRO network and can deliver a package that’s ready for the clinic. 🧬 Learn more about our innovative solutions: 🔬Syntekabio In Silico Biologics: includes Neo-ARS, our cutting-edge AI platform for personalized or universal #neoantigen prediction, so-called tumor-specific cancer vaccines, as well as Ab-ARS for the prediction of novel complementarity-determining regions (CDRs) of antibody heavy chains. 🚀 STB LaunchPad: proprietary disease-agnostic technology platform that can generate hits, leads, and ultimately drug candidates against multiple targets. 🌟 We look forward to meeting you to tell you more about how our platforms can generate new chemical entities and preclinical assets, simplifying and accelerating the path from discovery to development. 🤝 🗓️ Schedule a meeting via the partnering system at https://lnkd.in/dNYY4ts7 or drop by Booth 5435 to discuss how our innovative solutions can enhance your drug discovery efforts. #BIO2024 #drugdiscovery #BIOInternational #BIOConvention

InduPro Announces $85M Series A Financing https://lnkd.in/dHZJ3itc InduPro, Inc. , a biotechnology company defining protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, announced an $85 million Series A financing co-led by The Column Group and Vida Ventures with participation from investors, including MRL Ventures Fund (the therapeutics-focused venture fund of Merck & Co, Inc.), Emerson Collective and Euclidean Capital. The financing will support the advancement of the first expected clinical product candidate targeting cancer tissue based on the proximity of co-targeted pairs, from preclinical development to an expected IND filing in Q4 2025 for a Phase 1 clinical trial. It will also fuel a pipeline of novel bispecific antibodies and antibody drug conjugates (ADCs) that utilizes protein proximity for identification of novel tumor selective target pairings. Prakash Raman, Ph.D. joins as Chief Executive Officer of InduPro with more than two decades of biopharmaceutical business development and executive leadership experience, blending his… Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Merger & Acquisition Life Science / Healthcare 2023 Landscape Review Already this year we’ve seen Sanofi enter an agreement to acquire all outstanding shares of Inhibrx, Inc., as well as Johnson & Johnson’s recent acquisition of Ambrx Biopharma. 🔍 A quick review of Beacon Deals & Companies showed we identified 86 M&A deals last year 🔍 So, here’s one from every month … 🤝December: Bristol Myers Squibb Announced Definitive Merger Agreement to Acquire RayzeBio 🤝November: Selecta Biosciences Announces Merger with Cartesian Therapeutics 🤝October: Kyowa Kirin, Inc.- U.S. to Acquire Orchard Therapeutics 🤝September: Renovaro Biosciences Inc. and GEDiCube Sign Definitive Agreement to Combine 🤝August: Serina Therapeutics, Inc. and AgeX Therapeutics, Inc. Enter into Merger Agreement 🤝July: Biogen to Acquire Reata Pharmaceuticals, Inc. 🤝June: Talaris Therapeutics and Tourmaline Bio Entered into Merger Agreement 🤝May: Pyxis Oncology to Acquire Apexigen 🤝April: NKGen Biotech, Inc. to Become Publicly Traded Company via Business Combination with Graf Acquisition Corp. IV 🤝March: Flamingo Therapeutics Signed a Definitive Merger Agreement with Dynacure 🤝February: Kite Pharma Completed the Acquisition of Tmunity Therapeutics Incorporated 🤝January: Leap Therapeutics Acquires Flame Biosciences If you’re interested in learning more about how Beacon tracks the company and deal data in the Cell Therapy, Gene Therapy, RNA, ADC, Bispecific, Immune Tolerance, Checkpoint, Cytokine, DDR, TPD, Microbiome, Cancer Vaccine, or Oncolytic Virus landscapes drop me a message. #drugdevelopment #pharma #MnA #biotech

Fourteen biotech companies spearheading the antibody drug conjugate industry. "The antibody-drug conjugate (ADC) field is witnessing an expansion in the variety of conjugation techniques, linker chemistry, and payloads being used, moving beyond traditional tubulin inhibitors to include novel mechanisms of action. Investments in ADC research continue to grow, with significant funding rounds and acquisitions. For example, Novo Holdings’ $105 million investment in Alentis Therapeutics showcases the ongoing efforts to enhance ADC development platforms. Additionally, the market’s geographical expansion, particularly in China, reflects a global push towards innovative cancer therapies, as evidenced by multiple collaborations and licensing agreements aiming to bring novel ADCs to the clinic. Here are some of the key biotech companies in the ADC landscape." AbbVie Adcendo Adcentrx Therapeutics Alentis Therapeutics Araris Biotech AG AstraZeneca / Daiichi Sankyo, Inc. BioNTech SE Bristol Myers Squibb GSK MBrace Therapeutics Oxford BioTherapeutics Pfizer / Seagen Roche Takeda https://lnkd.in/eNxJt5ff #biotech #antibodydrugconjugates

Iambic Therapeutics announced the closing of an oversubscribed $50 million extension to its Series B financing. The Series B extension was funded by new investors Mubadala Capital, Exor Ventures and the Qatar Investment Authority (QIA), and existing investors Abingworth, Illumina Ventures, Nexus Ventures, Coatue, and Tao Capital. The extension adds to an oversubscribed $100 million Series B that closed in October and was co-led by Ascenta Capital and Abingworth, joined by NVIDIA and others.    Iambic Therapeutics' physics-informed AI-driven discovery platform has enabled a pipeline of novel small molecule therapeutics, including IAM1363, a highly selective, brain-penetrant inhibitor of wild-type and oncogenic mutant HER2 proteins currently in Phase 1 studies, and IAM-C1, a potential first-in-class selective dual CDK2/4 inhibitor. Proceeds from a combined >$150M Series B financing will be used to broaden and accelerate Iambic's clinical and pre-clinical oncology programs.    Ron Mazumder Charles Lin Bill Rastetter     Read the full press release: https://lnkd.in/eQk6jD96    This news follows another exciting announcement earlier that Thomas Miller, CEO of Iambic Therapeutics, has received the EY Entrepreneur Of The Year® 2024 Pacific Southwest Award. See EY’s full press release here: https://lnkd.in/eUShge_T Way to go, Tom!    #partnernews #SeriesB #biotech #lifescience #MachineLearning #AI #DrugDiscovery #healthcare

More moving and 'shaking' in the #OncologyDevelopment space: So soon after Merck inked their own deal, the MA biotech C4 Therapeutics, Inc. signs another with Merck KGaA, Darmstadt, Germany to seek out two #ProteinDegraders. #Oncology #MerckKGaA #Biotech #Innovation #Licensing #Pharma #Healthcare

 Major Partnerships in AI-focused biotech 🔬 Absci and AstraZeneca: A $247 million deal was announced in December 2023 to develop AI-designed anticancer antibodies. 🔬 BigHat Biosciences and AbbVie: A collaboration worth over $200 million to leverage AI for antibody development. 🔬 BigHat Biosciences and Almirall: A $610 million deal to create AI-designed therapeutics for dermatological diseases. 🔬 Sanofi and BioMap: A partnership potentially worth more than $1 billion to develop AI models for biological design. 🔬 Xaira Therapeutics, Co-founded by David Baker, is an AI-focused biotech that launched with over $1 billion in funding. It aims to use generative AI tools like diffusion models to design next-generation biologics. 🤝 These partnerships and innovations are not just significant; they are game-changers. They underscore the growing impact of AI in biotech, paving the way for faster and more efficient development of therapeutic antibodies. The integration of AI and biologics expertise is poised to revolutionize the industry, offering new hope for the treatment of various diseases. #artificalintelligence

𝗕𝗼𝘂𝗻��𝗹𝗲𝘀𝘀 𝗕𝗶𝗼 𝗯𝗼𝗹𝗱𝗹𝘆 𝗴𝗼𝗲𝘀 𝗽𝘂𝗯𝗹𝗶𝗰 𝘄𝗶𝘁𝗵 $𝟭𝟬𝟬𝗠 𝗜𝗣𝗢 Boundless Bio is bringing in $100 million from its IPO as the precision oncology company becomes the latest biotech to go public in 2024. The company has priced its 6.25 million shares at $16 apiece, squarely in the middle of the $15 to $17 range the biotech set out in a Securities and Exchange Commission filing last week. Those gross proceeds could swell to $115 million if underwriters take up the offer of buying an additional 937,500 shares at the same price. Boundless' stock is due to start trading on the Nasdaq Global Select Market this morning under the ticker “BOLD.” When ranked against the crop of biotech IPOs that emerged in the opening weeks of the year, Boundless sits toward the bottom of the scale. So far, preclinical gene editing company Metagenomi is the only traditional biotech to have brought in less than $100 million, while CG Oncology has retained the top spot for 2024 so far with its eyebrow-raising $380 million IPO in January. Boundless isn’t the only biotech IPO set for spring. Contineum Therapeutics also filed paperwork this month to raise money for phase 2 trials of its lead prospect and a Johnson & Johnson-partnered molecule. https://lnkd.in/eRBQpgwg

“In my experience, being first really matters, especially in oncology, where the people who win are usually the first or second to market and then there's a bunch of follow-on, me-too products,” Knowles said. "He compared the market potential of Affini-T to a company like Legend Biotech, a cell therapy biotech with an almost $13 billion market cap that’s partnered with Janssen on Carvykti." #DahliaConsulting #BiopharmaceuticalIndustry #CommercialLifeSciences #ManagementConsultant #LifeSciencesBusinessStrategy #GlobalPharma #GlobalBioTech #SupplychainOperations #CommercialOperations #CGTcommercialization #Manufacturing #QualityAssurance #OperationalExcellence #FinancialAnalysis #OpModelDesign #LifeScience #BioTechnology #Bioprocessing #Biosimilars #BioPharmaIndustry #MedicalResearch #CDMO #GMP #GMPbatch #GMPmanufacturing #GenomeEditing #GeneTherapy #CellTherapy #Car_T #mRNA #cGMP #ClinicalGradeManufacturing #ClinicalGradeProduction #BiologicsLicenseApplication #BLA #Pharmaceuticals #RegenerativeMedicine #FierceBiotech #Affini_T #IPO

Antibody Drug Conjugates (#ADCs) Keep Growing! Tubulis GmbH, a German ADC #biotech #startup, raises €128 million ($138.8 million) Series B2 financing to accelerate the clinical development of solid tumour-focused ADC pipeline. The financing round is co-led by EQT Life Sciences and Nextech Invest, with participation from current and new leading global biotechnology investors. According to MarketsandMarkets™’s report, the global ADCs market in terms of revenue was estimated to be worth $9.7 billion in 2023 and is poised to reach $19.8 billion by 2028, with a CAGR of 15.2% from 2023 to 2028. Other leading players in the global ADCs market include: - AbbVie/ ImmunoGen, Inc. - Adcendo - Adcentrx Therapeutics - Alentis Therapeutics - AstraZeneca/ Daiichi Sankyo, Inc. - BioNTech SE/ Duality Biologics - Bristol Myers Squibb - GSK - Innovent Biologics - Pfizer/ Seagen